

Peter Kolkhof

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8820821/publications.pdf>

Version: 2024-02-01

57
papers

7,114
citations

87888

38
h-index

149698

56
g-index

59
all docs

59
docs citations

59
times ranked

2992
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1014-1023.	0.7	50
2	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <i>European Heart Journal</i> , 2022, 43, 474-484.	2.2	341
3	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.	6.1	89
4	Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3220-3234.	5.4	65
5	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.	1.6	86
6	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. <i>European Journal of Heart Failure</i> , 2022, 24, 996-1005.	7.1	23
7	Molecular mechanisms and therapeutic targets for diabetic kidney disease. <i>Kidney International</i> , 2022, 102, 248-260.	5.2	112
8	Finerenone Reduces Renal ROR1 ⁺ T Cells and Protects against Cardiorenal Damage. <i>American Journal of Nephrology</i> , 2022, 53, 552-564.	3.1	6
9	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021, 143, 540-552.	1.6	171
10	Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 233-241.	1.7	17
11	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. <i>European Heart Journal</i> , 2021, 42, 152-161.	2.2	249
12	Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. <i>FASEB Journal</i> , 2021, 35, e21314.	0.5	12
13	Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis. <i>American Journal of Nephrology</i> , 2021, 52, 588-601.	3.1	31
14	Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. <i>American Journal of Nephrology</i> , 2021, 52, 642-652.	3.1	80
15	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.	2.8	74
16	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.	27.0	599
17	Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders – New perspectives for combination therapy. <i>Pharmacological Research</i> , 2021, 172, 105859.	7.1	37
18	Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1141-1157.	4.1	26

#	ARTICLE	IF	CITATIONS
19	The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway. <i>FASEB Journal</i> , 2020, 34, 12450-12465.	0.5	38
20	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229.	27.0	1,148
21	Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure. <i>European Journal of Heart Failure</i> , 2020, 23, 743-750.	7.1	16
22	Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy. <i>ESC Heart Failure</i> , 2020, 7, 3983-3995.	3.1	13
23	The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. <i>Biochemical Pharmacology</i> , 2019, 168, 173-183.	4.4	33
24	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356.	3.1	127
25	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.	3.1	112
26	Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 44-52.	1.9	8
27	Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. <i>Hypertension</i> , 2018, 71, 599-608.	2.7	149
28	The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. <i>Kidney International</i> , 2018, 93, 1344-1355.	5.2	109
29	Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. <i>Frontiers in Pharmacology</i> , 2018, 9, 1131.	3.5	61
30	Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1546-1555.	3.3	44
31	Corticosteroid receptors adopt distinct cyclical transcriptional signatures. <i>FASEB Journal</i> , 2018, 32, 5626-5639.	0.5	22
32	Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 121, 124-133.	1.9	32
33	Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2399-2407.	4.4	36
34	Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1216-1226.	6.1	68
35	30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. <i>Journal of Endocrinology</i> , 2017, 234, T125-T140.	2.6	174
36	Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 870-878.	2.7	92

#	ARTICLE	IF	CITATIONS
37	Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NF- κ B Pathway. <i>Hypertension</i> , 2017, 70, 1148-1156.	2.7	67
38	The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. <i>PLoS ONE</i> , 2017, 12, e0184888.	2.5	34
39	Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 402-411.	1.9	59
40	A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. <i>Circulation Journal</i> , 2016, 80, 1113-1122.	1.6	54
41	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114.	2.2	274
42	Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 271-305.	1.8	102
43	Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction. <i>Hypertension</i> , 2016, 67, 717-723.	2.7	69
44	Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 398-404.	6.1	50
45	Abstract 055: Benefit of Mineralocorticoid Receptor Antagonism in Acute Kidney Injury: Role of Smooth Muscle Rac1. <i>Hypertension</i> , 2016, 68, .	2.7	0
46	Abstract P298: Finerenone Protects Against the Acute and Chronic Consequences of Renal Ischemia/reperfusion Injury. <i>Hypertension</i> , 2016, 68, .	2.7	0
47	Nonsteroidal antagonists of the mineralocorticoid receptor. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 417-424.	2.0	100
48	Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1. <i>Journal of Biological Chemistry</i> , 2015, 290, 21876-21889.	3.4	116
49	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 884.	7.4	523
50	Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628. <i>PLoS ONE</i> , 2015, 10, e0145666.	2.5	12
51	Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 69-78.	1.9	265
52	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013, 34, 2453-2463.	2.2	419
53	Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. <i>European Journal of Heart Failure</i> , 2012, 14, 668-675.	7.1	72
54	Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases. <i>ChemMedChem</i> , 2012, 7, 1385-1403.	3.2	194

#	ARTICLE	IF	CITATIONS
55	Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. <i>Molecular and Cellular Endocrinology</i> , 2012, 350, 310-317.	3.2	129
56	Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. <i>FASEB Journal</i> , 2011, 25, 968-978.	0.5	65
57	A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule. <i>Journal of Biological Chemistry</i> , 2010, 285, 29932-29940.	3.4	157